Predictive value of tumor-infiltrating lymphocytes for neoadjuvant therapy response in triple-negative breast cancer: A systematic review and meta-analysis

Figure 5 Forest plot illustrating the correlation between tumor-infiltrating lymphocyte levels and pathological complete response rates across various neoadjuvant therapy regimens. TIL: Tumor-infiltrating lymphocyte; AC: Anthracycline combined with cyclophosphamide; AC-T: Anthracycline combined with cyclophosphamide followed by paclitaxel or docetaxel; TAC: Paclitaxel or docetaxel combined with anthracycline, and cyclophosphamide; AC-TCb: Anthracycline combined with cyclophosphamide followed by paclitaxel or docetaxel, and platinum; AC-T + Fu: Anthracycline combined with cyclophosphamide followed by paclitaxel or docetaxel, and fluorouracil.